Leap Therapeutics (NASDAQ:LPTX) Issues Earnings Results, Beats Estimates By $0.02 EPS

Leap Therapeutics (NASDAQ:LPTX) announced its quarterly earnings results on Monday. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.02, Zacks reports.

Leap Therapeutics Stock Up 43.6 %

Shares of LPTX opened at $0.56 on Wednesday. The stock has a market cap of $21.34 million, a PE ratio of -0.27 and a beta of 0.35. Leap Therapeutics has a 12-month low of $0.39 and a 12-month high of $4.79. The business has a 50-day simple moving average of $0.89 and a two-hundred day simple moving average of $2.23.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on LPTX. Baird R W downgraded Leap Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 29th. Robert W. Baird downgraded shares of Leap Therapeutics from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $9.00 to $1.25 in a research note on Wednesday, January 29th. Finally, HC Wainwright cut shares of Leap Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, January 29th.

About Leap Therapeutics

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.